Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lacosamide Reduces Partial-Onset Seizures in PIII: Daiichi Sankyo, UCB
December 22, 2015
- Shionogi, Mundipharma Seal Agreement on Ethical Isodine Products
December 22, 2015
- CSL Behring Files rIX-FP for Hemophilia B Treatment in Japan
December 22, 2015
- PeptiDream Ties Up with Genentech for Peptide Discovery
December 22, 2015
- Eisai to Transfer Manufacturing Subsidiary to Alfresa
December 21, 2015
- 80% Target for Generics Presents “Business Opportunity” for Alfresa Fine Chemical: Pres. Miyadera
December 21, 2015
- Acucela Establishes Japanese Subsidiary to Strengthen Business in Japan
December 21, 2015
- BMKK, Ono Initiate Multinational PIIIb Study of Orencia in Japan
December 21, 2015
- Ohara Files Japan NDA for ALL Drug Crisantaspase
December 18, 2015
- Taiho, Meiji Seika Pharma to Comarket Allergy Drug
December 18, 2015
- AbbVie Files Viekirax for Genotype 2 Hepatitis C
December 18, 2015
- Opdivo Gets Lung Cancer Indication in Japan: Ono
December 18, 2015
- Takeda to Divest Respiratory Biz to AstraZeneca
December 17, 2015
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
- Takeda, Kyoto University Kick Off iPS Projects Targeting 6 Diseases
December 16, 2015
- LEO Pharma “Eager to Do More” after Astellas Deal to Expand Globally: CEO
December 16, 2015
- JPO Says Patents for Alimta Vitamin Therapy Valid until 2021
December 16, 2015
- Mitsubishi Tanabe Gains Exclusive Rights to Akebia’s Anemia Drug in Asia
December 16, 2015
- Mundipharma Poised to Expand Japan Operations by Tapping Isodine Brand: Asia Head
December 15, 2015
- Daiichi Sankyo Looking for a Partner to Codevelop GPR119 Agonist: CEO Nakayama
December 15, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…